Konference: 2012 37th Congress ESMO – účast ČR
Téma: Poster, Poster presentation III
Číslo abstraktu: 1464P
Autoři: Doc. MUDr. Luboš Holubec (jr.), Ph.D., MBA; MUDr. Ondřej Fiala; MUDr. Vít Martin Matějka; MUDr. Jiří Podlipný, PhD; MUDr. Jana Dreslerová; MUDr. Jindra Vrzalová; Prof. MUDr. Ondřej Topolčan, CSc.; prof. MUDr. Jindřich Fínek, Ph.D.; MUDr. Ing. Tomáš Svoboda, PhD.
To assess the differences in the serum levels of Brain-derived neurotrophic factor (BDNF), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10) and epidermal growth factor (EGF) in oncology patients with symptoms of depression and in oncology patients without symptoms of depression.
We administered the following self – report questionnaires to the hospitalized oncology patients (n = 32): Zung´s Self-Rating Depression Scale (ZSDS) and Symptom Check List Psychiatric Rating Scale (SCL 90). We also collected blood samples from these patients for the detection of the following factors: BDNF, IL-6, IL-8, IL-10 and EGF. The procedures had been fully explained to all patients and written informed consent had been obtained. The patients were divided into two groups according to the scores in ZSDS: a group with the presence of symptoms of depression (n = 20) and a group without the symptoms of depression (n = 12). The differences in the levels of BDNF, interleukins and EGF between the groups were statistically assessed by Wilcoxon rank-sum test.
Oncology patients with the symptoms of depression showed significantly lower levels of BDNF (medians 1452.3 vs 3229.0 pg/ml, p = 0.014). There were no significant differences in the levels of IL-6, IL-8, IL-10 and EGF between the groups.
This result supports the hypothesis of diminished neuroplasticity in oncology patients with the symptoms of depression as measured by the serum levels of BDNF. This study was supported by research project MSM 0021620819.
All authors have declared no conflicts of interest.
Datum přednesení příspěvku: 1. 10. 2012